> U.S. regulators have strongly suggested that Vasogen undertake a study to confirm the clinical data on Celacade before filing for approval of the heart medication. Report
> EndoCeutics has pulled its IPO, citing market conditions and a changeup in its schedule for clinical trials. The Canadian biotech is developing hormone therapies for breast cancer and endocrine-related disorders. Report
> Ventana Medical Systems has taken a cool attitude toward Roche's $3 billion takeover bid. Investors, though, showed more enthusiasm, bidding up Ventana stock 48 percent on the news from yesterday. Report
> ViroPharma's hepatitis C therapy has been fast-tracked by the FDA. Report
> Sanofi's Taxotere has been granted a priority review by the FDA for head and neck cancer. Report
> CytRx announced promising data from the six-month, open-label extension of its completed Phase IIa clinical trial with arimoclomol in ALS volunteers. Release
> As states begin to track pharma gifts to doctors, psychiatrists are increasingly coming up as top beneficiaries for pharma payments. Report
And Finally... Scientists have developed a new method using nanoparticles to deliver drugs. Report